Edoxaban

DB09075ApprovedInvestigationalSmall moleculeAnticoagulantsDirect factor Xa inhibitorsFactor Xa Inhibitors

Edoxaban is a novel oral anticoagulant used for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor.

Chemical structure of Edoxaban
Mechanism
Curator reviewed
Primary indication
Edoxaban is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).Curator reviewed · 4 structured indications
Formula / weight
C24H30ClN7O4S · 548.06 g/mol (avg)
First approval
Canada, 2017 · United States, 2015 · European Union, 2016
Code names
DU-176 · DU-176b
Brand names
  • Lixiana
  • Roteas
  • Savaysa

Resolves to

Compound
UNIINDU3J18APOCAS480449-70-5ChEMBLCHEMBL1269025ChEBI85973PubChem10280735KEGGD09546
Clinical / RWD
RxNorm1599538ATCB01AF03PharmGKBPA166128806
Structure
InChIKeyHGVDHZBSSITLCT-JLJPHGGASA-NSMILESCN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1
Targets
P00742F10
Transporters
P08183ABCB1

What you can answer from here — as of October 01, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
1,319Drug interactionsStructured to mechanism, not free text
Sign in
139Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
150Marketed productsAcross 10 countries and 19 labellers
Sign in
1ATC codeIncluding every combination product, plus 13 drug categories
Sign in
9+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Edoxaban, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In